{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T03:08:42Z","timestamp":1779073722780,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed\/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B\u2010cell maturation antigen (BCMA) on myeloma cells to induce T cell\u2013mediated myeloma cell cytolysis. The recommended subcutaneous elranatamab dosing consists of fixed step\u2010up doses of 12\u2009mg on day 1 and 32\u2009mg on day 4 to mitigate the incidence and severity of cytokine release syndrome (CRS), followed by the full fixed dose of 76\u2009mg once weekly (QW) from weeks 2 to 24. In responders, 76\u2009mg QW is reduced to every 2\u2009weeks (Q2W) after \u2265\u20096 QW cycles and to every 4\u2009weeks after \u2265\u20096 Q2W cycles. The full dose (76\u2009mg QW) results in a higher probability of achieving an objective response versus lower doses without worsening the safety profile. This regimen was based on the collective safety, efficacy, pharmacokinetic, and pharmacodynamic data from MagnetisMM\u20101, \u20102, \u20103, and \u20109. In the pivotal MagnetisMM\u20103 study, in patients with BCMA\u2010naive RRMM, elranatamab resulted in a 61.0% overall response rate; 37.4% achieved complete response or stringent complete response. Median duration of response was not yet reached; the probability of maintaining response at 30\u2009months was 61.0%. Median progression\u2010free and overall survival were 17.2 and 24.6\u2009months, respectively. In MagnetisMM\u20103 patients, common adverse events (\u2265\u200940%; any grade\/grade 3\/4) included infections (71.7%\/38.5%), CRS (58.8%\/0.5%), anemia (53.5%\/42.2%), neutropenia (46.0%\/44.4%), and diarrhea (42.8%\/3.2%). Elranatamab demonstrated deep and durable responses, a manageable safety profile, and low\u2010grade CRS with predictable timing. Elranatamab is being further evaluated as monotherapy or combination therapy in earlier treatment lines.<\/jats:p>","DOI":"10.1111\/cts.70554","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:02:34Z","timestamp":1777435354000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elranatamab: Mechanism of Action, Clinical, and Translational Science"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9825-5890","authenticated-orcid":false,"given":"Mohamed","family":"Elmeliegy","sequence":"first","affiliation":[{"name":"Oncology Research and Development Pfizer, Inc.  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Viqueira","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer SLU  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooneh","family":"Soltantabar","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer, Inc.  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-3144","authenticated-orcid":false,"given":"Hoi\u2010Kei","family":"Lon","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer, Inc.  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-2213","authenticated-orcid":false,"given":"Kamrine","family":"Poels","sequence":"additional","affiliation":[{"name":"Pfizer Research &amp; Development Pfizer, Inc.  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blerta","family":"Shtylla","sequence":"additional","affiliation":[{"name":"Pfizer Research &amp; Development Pfizer, Inc.  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Irby","sequence":"additional","affiliation":[{"name":"Pfizer Research &amp; Development Pfizer, Inc.  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Bompiani\u2010Myers","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer, Inc.  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Pfizer Research &amp; Development Pfizer, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hibma","sequence":"additional","affiliation":[{"name":"Pfizer Research &amp; Development Pfizer, Inc.  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241275797"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0007"},{"key":"e_1_2_15_4_1","unstructured":"FDA Center for Drug Evaluation and Research \u201cElranatamab (ELREXFIO) Multidisciplinary Review 2023 \u201daccessed March 27 2025."},{"key":"e_1_2_15_5_1","unstructured":"Pfizer \u201cElranatamab\u2010bcmm (ELREXFIO) Summary of Product Characteristics \u201d(2023)."},{"key":"e_1_2_15_6_1","unstructured":"Pfizer \u201cElranatamab\u2010bcmm (ELREXFIO) Package Insert \u201d(2025)."},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae068"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01134-8"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01170-4"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190341"},{"key":"e_1_2_15_13_1","unstructured":"FDA Center for Drug Evaluation and Research \u201cBelantamab Mafodotin\u2010blmf (BLENREP) Multidisciplinary Review 2020 \u201daccessed May 7 2025."},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007625"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01168-y"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70130"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-025-00585-z"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3533"},{"key":"e_1_2_15_19_1","unstructured":"R.Niesvizky B.Arnulf M.Mohty et\u00a0al. \u201cClinical Factors Related to Cytokine Release Syndrome and Elranatamab Dosing Recommendations After a Dose Interruption \u201dpresented at the 49th Annual Meeting of the Japanese Society of Myeloma (JSM) Fukuoka Japan May 31\u2013June 2 2024."},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8033"},{"key":"e_1_2_15_21_1","doi-asserted-by":"crossref","unstructured":"H. M.Prince N. J.Bahlis P.Rodriguez\u2010Otero et\u00a0al. \u201cMagnetisMM\u20103: Long\u2010Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients With Relapsed or Refractory Multiple Myeloma \u201dpresented at the 66th ASH Annual Meeting and Exposition (P4738) San Diego California December 7\u201310.","DOI":"10.1182\/blood-2024-208192"},{"key":"e_1_2_15_22_1","doi-asserted-by":"crossref","unstructured":"A.Nooka A.Lesokhin M.Mohty et\u00a0al. \u201cEfficacy and Safety of Elranatamab in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM) and Prior B\u2010Cell Maturation Antigen (BCMA)\u2010Directed Therapies: A Pooled Analysis From MagnetisMM Studies \u201dpresented at the American Society of Clinical Oncology (ASCO) Chicago Illinois June 2\u20136 2023.","DOI":"10.1016\/S2152-2650(23)00826-1"},{"key":"e_1_2_15_23_1","doi-asserted-by":"crossref","unstructured":"X.Leleu N. J.Bahlis P.Rodriguez\u2010Otero et\u00a0al. \u201cImpact of Hypogammaglobulinemia and Immunoglobulin Replacement Therapy on Infection Rate in Patients With RRMM Treated With Elranatamab: Post\u2010Hoc Analysis From MagnetisMM\u20103 \u201dpresented at the 20th International Myeloma Society (IMS) Meeting (P286) Athens Greece September 27\u201330 2023.","DOI":"10.1016\/S2152-2650(23)01904-3"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2461987"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00735-z"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_2_15_29_1","unstructured":"Bristol Myers Squibb \u201cIdecabtagene Vicleucel (ABECMA) Package Insert \u201d(2021)."},{"key":"e_1_2_15_30_1","unstructured":"Janssen Biotech \u201cCiltacabtagene Autoleucel (CARVYKTI) Package Insert \u201d(2022)."},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010024\u201000821\u20101"},{"key":"e_1_2_15_32_1","unstructured":"R.Popat C.Touzeau A.Perrot et\u00a0al. \u201cFirst\u2010In\u2010Human Study of JNJ\u201079635322 (JNJ\u20105322) A Novel Next\u2010Generation Trispecific Antibody in Patients With Relapsed\/Refractory Multiple Myeloma: Initial Phase 1 Results \u201dpresented at the Annual EHA Congress Milan Italy June 12\u201315 2025."},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03913-0"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194830"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70554","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T02:57:21Z","timestamp":1779073041000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/cts.70554"],"URL":"https:\/\/doi.org\/10.1111\/cts.70554","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2025-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70554"}}